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ABSTRACT  
 
Objectives: Childhood trauma is common among street-involved youth, and is 
associated with injection drug use. Illicit 3,4-Methylenedioxymethamphetamine 
(MDMA) use is also common among street-involved youth, and data suggests this 
substance has clinical utility in management of post-traumatic stress disorder (PTSD) 
and associated harms. Despite this, little is known about co-occurring patterns of 
MDMA use and injection drug use.  
 
Methods: Data were derived from a prospective cohort of street-involved youth using 
illicit drugs in Vancouver, Canada. Using multivariable generalized estimating equation 
logistic regression, we examined the association between MDMA use and the use of 
injection drugs, adjusting for confounders such as polysubstance use and 
sociodemographic factors.  
 
Results: 4941 surveys from 1208 participants between September 2005 and May 2015 
were included. Of these, 829 (68.6%) were male, 815 (67.5%) reported white ethnicity, 
and median age was 21.7 years. Overall, 599 (49.6%) participants reported MDMA use, 
544 (45.0%) reported injection drug use, and 244 (20.2%) reported concurrent MDMA 
and injection drug use at least once during the study period.  In multivariable analyses, 
regular MDMA use was significantly negatively associated with injection drug use 
(Adjusted Odds Ratio [AOR] = 0.57, 95% CI: 0.46-0.69).  
 
Discussion: After accounting for socio-demographic factors and polysubstance use, 
periods of reported regular MDMA use were negatively associated with reported 
injection drug use among this cohort. These findings suggest that, unlike the use of 
most other non-injection drugs, illicit MDMA use does not appear to promote injection 
drug use, but rather is associated with a reduced likelihood of injection drug use.    
 
Keywords: Injection drug use, 3,4-Methylenedioxymethamphetamine (MDMA), 
Ecstasy, childhood trauma, PTSD 
Word count: 250 
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1.1 INTRODUCTION 
The illicit use of 3,4-Methylenedioxymethamphetamine (MDMA), a component 
of the drug frequently referred to as “ecstasy” or “molly”,  is commonly associated with 
illicit polysubstance use (Schifano et al., 1998). However, evidence also shows that 
MDMA has potential therapeutic effects, and is thought to promote behaviours that are 
useful in a therapeutic setting. These include authenticity, defined as an awareness of 
and congruence between an individual’s thought process and actions, in addition to 
prosociality and autobiographical disclosure (Baggott et al., 2016; Carhart-Harris et al., 
2014; Wardle et al., 2014). As such, MDMA was used in psychotherapy until it became a 
scheduled substance in the 1980s (Jerome et al., 2013). Subjective reports from this 
period in samples of people with psychological difficulties, such as depression and 
anxiety, attribute MDMA use with improved insight into their condition and increased 
self-acceptance (Greer and Tolbert, 1986).  
More recently, MDMA use in therapeutic settings has been reported to have 
durable efficacy in combination with psychotherapy for the treatment of post-traumatic 
stress disorder (PTSD), and this finding has been replicated in clinical trials (Bouso et 
al., 2008; Mithoefer et al., 2011; Mithoefer et al., 2013; Oehen et al., 2013; Yazar-Klosinski 
and Mithoefer, 2017). PTSD is a condition defined by re-experiencing, avoidance, 
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arousal, and negative changes in mood and cognition that follow the experience of a 
traumatic event (Armour et al., 2016). In the therapeutic setting, MDMA is thought to 
help allow individuals with PTSD to confront and form a new relationship with their 
trauma/traumatic memories, and Phase II clinical trials have demonstrated that 
following MDMA-assisted psychotherapy, 66.7% of participants no longer met the 
clinical diagnosis for PTSD at 12-month follow-up (Yazar-Klosinski and Mithoefer, 
2017).  
The experience of trauma, particularly childhood trauma, is known to be 
associated with the initiation and ongoing use of injection drugs (Debeck et al., 2013; 
Kerr et al., 2009; Quinn et al., 2016; Taplin et al., 2014). Street-involved youth, defined as 
being homeless or at risk of homelessness and spending a substantial amount of time on 
the street or being heavily involved in the street economy, have been shown to 
experience high levels of childhood maltreatment (Stoltz et al., 2007). This population is 
also at high risk of problematic substance use, including injection drug use (Debeck et 
al., 2013; Kerr et al., 2009). Although data suggests that MDMA has therapeutic utility in 
the treatment of PTSD, little is known about the relationship between illicit use of 
MDMA, psychological distress, and the use of injection drugs among individuals who 
have experienced significant trauma.  One study that utilized a national monitoring 
system of people who report MDMA use found that individuals who reported regular 
use of MDMA also report elevated psychological distress compared with the general 
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population, with polysubstance use and binge substance use being strong predictors of 
distress in this population.  The use of MDMA itself, however, was not independently 
associated with levels of distress (George et al., 2010).  
It is commonly assumed that all non-injection substance use, including but not 
limited to MDMA, increases risk of injection drug use and related harms (Trenz et al., 
2012), but recent data suggests that this may not be universally true. For instance, lower 
rates of injection drug use initiation have been documented among street-involved 
youth who frequently use cannabis (Reddon et al., 2018). It has also been established 
that increasing access to cannabis is associated with lower opioid overdose mortality 
rates (Bachhuber et al., 2014).  It is possible that the clinical utility of cannabis in 
addressing chronic pain, a frequent root cause of substance use and misuse, might play 
a role in these findings. Likewise, considering evidence suggesting that MDMA has 
clinical utility in addressing trauma, and the established relationship between trauma 
and subsequent problematic substance use, a careful exploration of the relationship 
between illicit MDMA use and higher risk substance use among populations with 
elevated levels of childhood trauma is warranted.  
Using data from a prospective cohort of street-involved youth who use illicit 
substances in Vancouver, Canada we examine the association between regular MDMA 
use and the use of injection drugs. Given the evidence around the therapeutic value of 
MDMA in the treatment of trauma and associated harms, we hypothesized that MDMA 
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use may independently be associated with decreased risk of injection drug use in this 
study population, despite the commonly held assumption that all non-injection illicit 
drug use is a gateway to more problematic substance use.  
 
2.1 MATERIAL AND METHODS 
Data for this study were derived from the At-Risk Youth Study (ARYS), an 
ongoing open prospective cohort. This cohort has been described in detail previously 
(Wood et al., 2006). Briefly, since 2005, participants have been recruited through self-
referral, word-of-mouth and street outreach. Eligibility criteria include residing in the 
Greater Vancouver region and being at least 14-26 years of age at the time of 
recruitment. At baseline and semi-annually thereafter, participants complete an 
interviewer-administered questionnaire. All participants provide written informed 
consent and are provided with a $30 CAD stipend at each study visit. 
All participants who completed a study visit between September 2005 and May 
2015 were included in the present analyses. Use of specific illicit drugs were divided 
into substance type, route of administration, and frequency of use (no use, less than 
once per month, 1-3 times per month, once per week, 2 or 3 times per week, once per 
day). The primary outcome of interest was reported use of any injection drugs in the 
previous six months (dichotomous, yes vs. no) The primary exposure of interest was 
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MDMA use in the last six months. Three categories for MDMA use were defined. The 
reference category was defined as no reported MDMA use in the last six months. The 
second category was regular MDMA use, defined as reports of using MDMA at least 
once per month. The third category was infrequent MDMA use defined as reports of 
using MDMA less than one per month over the last six months. Based on existing 
literature, we selected other explanatory variables that we hypothesized might be 
associated with regular use of MDMA and injection drugs. These included the 
following socio-demographic and behavioural variables: age at baseline (per year 
older); gender (male vs. female); ethnicity (White vs. Non-White); homelessness (yes vs. 
no); education (≥ secondary vs. < secondary); regular employment (yes vs. no); 
engagement with substance use treatment (yes vs. no); and residence in the Downtown 
Eastside neighborhood of Vancouver (yes vs. no). We also considered variables related 
to other illicit substance use patterns, including: non-injection cocaine use (yes vs. no); 
non-injection injection heroin use (yes vs. no); non-injection crystal methamphetamine 
use (yes vs. no); non-injection non-medical pharmaceutical opioid use (yes vs. no); daily 
cannabis use (yes vs. no); and heavy alcohol use, defined by the National Institute for 
Alcohol Abuse and Alcoholism (NIAAA) (yes vs. no). Finally, we also included past 
mental health diagnosis (yes vs. no) and scores from the Childhood Trauma 
Questionnaire (CTQ), a 28-item survey assessing physical, sexual and emotional abuse 
in addition to physical and emotional neglect. This survey is valid and reliable when 
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applied to adolescent and substance-using samples (Bernstein et al., 2003). We 
compared “moderate and severe” range scores (13-25) against “none and low” range 
scores (5-12). Aside from age, gender, ethnicity, education, mental health diagnosis, and 
scores from the CTQ, all variables were treated as time-updated and refer to the six-
month period prior to the interview. 
 
 
2.2 Statistical Analyses 
We first examined sample characteristics at baseline, stratified by reported 
injection drug use, using the Pearson’s Chi-squared test (for binary variables) and 
Mann-Whitney test (for continuous variables). We then examined these characteristics 
throughout the study period. Since analyses of factors potentially associated with 
injection drug use included serial measures for each participant across the study period 
at six month intervals, we used generalized estimating equations (GEE) with logit link. 
This method provides standard errors adjusted by multiple observations per person 
using an exchangeable correlation structure. This methodology considers data from 
every participant follow-up visit while appropriately accounting for differences in the 
number of observations for each participant.  
To account for possible confounding and calculate the best effect estimate, we 
then fit a multivariable model using an a priori-defined modeling strategy proposed by 
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Greenland et al (Maldonado and Greenland, 1993). We used a conservative p-value of 
0.10 in the bivariate analyses to determine whether a secondary explanatory variable 
was considered as a potential confounder in the relationship between the primary 
explanatory variable and the outcome and for inclusion in a full multivariate model. 
Then, reduced models were constructed in a manual stepwise approach, removing a 
single secondary explanatory variable each time. Specifically, the value of the coefficient 
for the primary explanatory variable in the full model and each reduced model was 
compared, and the secondary explanatory variable corresponding to the smallest 
relative change was removed. The process was repeated until the smallest relative 
change in the coefficient for any category of the primary explanatory variable from the 
full model was greater than 5%. 
We also recognized that there might be systematic group differences between 
participants who regularly engage in MDMA use and those who do not. Further, these 
same differences may exist between participants who inject drugs and those that do not.  
In order to minimize these possible systematic group differences, we conducted a sub-
analysis which restricted the sample to participants who reported MDMA use at least 
once during the study period and also reported injection drug use at least once during 
the study period, and examined bivariable and multivariable associations for this 
subsample using the same approach outlined above. All p-values were two-sided. All 
statistical analyses were performed using R, version 3.2.4 (Vienna, Austria 2016). 
Gaddis et al. Periods of Regular MDMA Use… 
 
10 
 
 
3.1 RESULTS 
In total, 1208 participants were included in the present study between September 
2005 and May 2015. Of these, 829 (68.6%) were male, 815 (67.5%) self-reported white 
ethnicity and the median age at baseline was 21.7 years (interquartile range *IQR+ = 19.8 
– 23.5). The median number of study visits per participant was 3 (IQR = 1 – 5). For the 
846 participants who had more than one study visit, the median follow-up time per 
participant was 24.5 months (IQR = 15.5 – 58.4). The baseline prevalence of MDMA use 
among participants who completed two or less study visits was 35.4% vs. 35.8% among 
those with greater than two study visits (p= 0.894). The baseline prevalence of injection 
drug use among participants who completed two or less study visits was 34.7% vs. 
31.8% among those with greater than two study visits (p= 0.304). 
Four hundred (33.1%) participants reported injection drug use at baseline and 
430 (35.6%) participants reported MDMA use at baseline (although six participants who 
reported MDMA use did not provide details on the frequency of use). Over the course 
of the study period, 544 participants (45.0%) reported injection drug use at least once 
and 599 participants (49.6%) reported use of MDMA at least once. A total of 244 
participants (20.2%) reported both the use of MDMA at least once during the study 
period and also reported injection drug use at least once during study period. Overall, 
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4941 observations were included in the analysis. A total of 1018 (20.6%) of these 
observations included reports of any MDMA use in the last six months, with 426 (8.6%) 
reports of regular use (at least once per month) and 583 (11.8%) reports of infrequent 
MDMA use (less than once per month).  
The baseline characteristics of the sample are reported in Table 1 and the results 
of the bivariate and multivariable GEE analyses of factors associated with injection drug 
use are presented in Table 2.  In bivariate analysis, regular MDMA use was negatively 
associated with the use of injection drugs during the previous six month period (Odds 
Ratio [OR] = 0.60, 95% Confidence Interval [CI] = 0.50-0.72) and infrequent use was not 
significantly associated with injection drug use (OR = 0.99, 95% CI = 0.86-1.15). In the 
multivariable model, regular MDMA use remained negatively associated with reported 
use of injection drugs (Adjusted Odds Ratio [AOR] = 0.57, 95% CI = 0.46-0.69) and 
infrequent MDMA use was not significantly associated with injection drug use (AOR = 
0.95, 95% CI = 0.81-1.11). Non-injection use of non-medical pharmaceutical opioids 
(AOR = 1.35, 95% CI = 1.11-1.65), homelessness (AOR = 1.21, 95% CI = 1.08-1.36), and 
physical abuse (AOR = 1.25, 95% CI = 0.98-1.59) were positively associated with 
injection drug use, while heavy alcohol was negatively associated with the injection 
drug use (AOR = 0.71, 95% CI = 0.63 – 0.81).  
The sub-analysis included 224 participants who reported use of MDMA at least 
once during the study period and who also reported injection drug use at least once 
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during study period. In this multivariable model, regular MDMA use remained 
negatively associated with periods of injection drug use (AOR = 0.41, 95% CI = 0.28-0.61) 
while infrequent MDMA use was not significantly associated with periods of injection 
drug use (AOR = 1.11, 95% CI = 0.80-1.53). Non-injection heroin use (AOR = 1.98, 95% CI 
= 1.37-2.87) and homelessness (AOR = 1.46, 95% CI = 1.11-1.91) were positively 
associated with periods of injection drug use, and heavy alcohol use remained 
negatively associated with periods of injection drug use (AOR = 0.53, 95% CI = 0.40 – 
0.70). The model was also adjusted for non-injection non-medical pharmaceutical opioid 
use and emotional neglect (all p >0.05). 
 
4.1 DISCUSSION 
 Our results indicate that periods of reported regular MDMA use are negatively 
associated with reported injection drug use, even after adjustment for polysubstance 
use and socio-demographic factors. This observed relationship remained consistent in a 
sub-analysis restricted to participants with a history of both MDMA and injection drug 
use. Although preliminary, these findings may be rooted in the acute and enduring 
prosocial and therapeutic effects that observational, experimental, and clinical studies 
suggest MDMA may have. 
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In experimental settings, MDMA use has been shown to support social outcomes 
such as increased response to positive emotional stimuli and decreased response to 
negative emotional stimuli (Bedi et al., 2010; Bedi et al., 2009; Hysek et al., 2014b; 
Kirkpatrick et al., 2014; Schmid et al., 2014; Wardle and de Wit, 2014). MDMA use  has 
also  been demonstrated to improve ability to read socio-emotional information such as 
facial expressions (Bedi et al., 2010; Hysek et al., 2012; Wardle and de Wit, 2014), 
improve favorability of social interactions (Wardle et al., 2014), increase empathy (Bedi 
et al., 2010; Hysek et al., 2014a; Kuypers et al., 2014; Schmid et al., 2014) and altruistic 
ability and behaviours (Hysek et al., 2014a; Kirkpatrick et al., 2015). These prosocial 
attributes are thought to underlie the clinical utility of MDMA.  
MDMA use has been shown to be beneficial in therapeutic settings for the 
treatment of PTSD by helping individuals manage the emotionally demanding process 
of decoupling the re-experience of trauma from actual threat (McLean and Foa, 2013; 
Steenkamp and Litz, 2014). As some aspects of the usefulness of MDMA in the 
therapeutic context are thought to be derived from the improved social outcomes 
observed in experimental settings, these could possibly extend to non-clinical illicit use 
of the substance and the behaviours that coincide with it. Given that many youth who 
engage in sustained problematic substance use are also survivors of childhood trauma 
(Taplin et al., 2014), one possible interpretation for the observed negative association in 
our sample between MDMA use and injection drug use could be that regular illicit 
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MDMA use may mediate some negative effects of trauma and discourage harmful 
substance use behaviours such as drug injecting.  
Previous work that also utilizes this cohort of street-involved youth suggests that 
childhood trauma, in particular physical abuse and emotional neglect, are not only 
commonly experienced in this sample, but are also predictive of progression to injection 
drug use (Debeck et al., 2013). Despite data suggesting therapeutic value of MDMA in 
the treatment of PTSD, and the commonplace illicit use of this substance, little is known 
about the correlates of MDMA use in populations experiencing high levels of trauma. 
The results from this sample, although preliminary, suggest that illicit MDMA use, and 
the constellation of other behaviours that surround it, may play a role in harm 
reduction. Further, it should be noted that the observed association is largely limited to 
participants who report using the substance at least monthly, and this frequency of use 
is congruent with current clinical trials (Mithoefer et al., 2013; Yazar-Klosinski and 
Mithoefer, 2017). Despite this, it is important to recognize the numerous inherent 
difficulties in comparing illicit use with the carefully managed containment of the 
therapeutic setting, which among numerous other benefits is essential to minimize the 
potential adverse events that can be associated with illicit MDMA use, including 
extended depressed mood, rhabdomyolysis and serotonin syndrome, among others 
(Michael White, 2014). It is equally important to note that illicit MDMA use has been 
shown to be associated with an array of harm reduction behaviours, such as the 
Gaddis et al. Periods of Regular MDMA Use… 
 
15 
 
avoidance of solitary substance use, and the use of test kits to determine substance 
identity and purity (Davis and Rosenberg, 2016; Davis and Rosenberg, 2017), and these 
behaviours may extended to other substance use and may help explain the observed 
associations in the current study. 
Compared to non-injection use of other illicit drugs, such as heroin and 
methamphetamine, the profile of harms and likelihood of progression to substance use 
disorder associated with the use of MDMA are known to be less severe (Nutt et al., 
2010). Studies that have followed post-experimental and post-clinical use of MDMA by 
participants/patients have identified few instances of craving or illicit use (Mithoefer et 
al., 2013). Outside of the experimental/clinical context, it is somewhat difficult to isolate 
the sequelae of MDMA use from that of poly-substance use (Schifano et al., 1998; Topp 
et al., 1999), but people that use MDMA have been found to exhibit an increased 
prevalence of mental health concerns (Parrott et al., 2000). Despite this finding, it seems 
that these concerns often predate use of MDMA (Lieb et al., 2002; Pedersen and 
Skrondal, 1999). A longitudinal study found that youth who use MDMA are more likely 
to use other illicit substances, but are not more likely to engage in sustained use of 
MDMA (von Sydow et al., 2002). Due to wide illicit availability, a comparatively less 
harmful risk profile, and possible therapeutic influence, further investigation is 
warranted to better understand the possible role that illicit MDMA use may play in 
poly-substance use and related harms. 
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Our results also indicate that heavy alcohol use was negatively associated with 
injection drug use. This finding is consistent with existing literature characterizing 
alcohol use among injection drug users. A study utilizing a national monitoring system 
of people who regularly use MDMA found that rates of concurrent alcohol use were 
significantly lower among those who also reported injection drug use (White et al., 
2006). It’s possible that people who use injection drugs engage in heavy drinking as a 
replacement behaviour during periods of abstinence from injection drugs. It is also 
possible that regular MDMA use is strongly associated with regular use of alcohol.  
Our study has several limitations. Most importantly, this is an observational 
study and we cannot infer causation from the observed associations. This sample is not 
random, as it is drawn from street-involved youth using street outreach methods and 
snowball sampling. Therefore, our findings may not generalize beyond this population. 
Further, our study includes data across ten years, during which time the composition of 
illicit MDMA and the culture surrounding its use in this cohort may have shifted, each 
potentially contributing to associated behaviors. Other limitations inherent in our study 
design include self-report of MDMA and injection drug use and frequency, and also 
unknown identity, composition and purity of reported drugs consumed. Poly-substance 
use is prevalent in our sample, and despite our best attempts to adjust for relevant 
confounders, we cannot ascertain the exact role of individual substances in the 
complicated constellation of poly-substance use observed among many of our 
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participants. For instance, MDMA use may simply coincide with a reduced likelihood 
of injection drug use without directly contributing to it. Although our observations are 
consistent with prior research demonstrating that MDMA use in therapeutic settings 
can help treat PTSD, which is known to be associated with injection drug use, further 
study is needed. An important focus of further study should be ongoing monitoring of 
indicators related to psychological trauma and well-being during the illicit use of 
MDMA and other substances, which is a significant limitation of this study.    
 
4.2 Conclusions 
In summary, we found that periods of regular MDMA use were independently 
associated with a reduced likelihood of reporting injection drugs in a prospective 
observational cohort of street-involved youth who use illicit drugs, and have 
experienced significant childhood trauma. While the experience of trauma is a known 
risk factor for injection drug use, and evidence indicates that MDMA in therapeutic 
settings has clinical utility in the treatment of PTSD, little is known about the correlates 
of illicit MDMA use in individuals who have experienced significant trauma. Although 
preliminary, our findings suggest that after accounting for the complex constellation of 
poly-substance use in this population and other predictive factors, the illicit use of 
MDMA does not appear to promote injection drug use, but rather is associated with a 
reduced likelihood of injection drug use. Further research in this area is warranted.  
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Table 1: Factors associated with injection drug use at baseline among 1208 at-risk youth in 
Vancouver, Canada 
Characteristic 
Yes 
n (%) 
n = 400 
No 
n (%) 
n = 808 
Odds Ratio 
(95% CI) 
p - value 
MDMA†     
Regular use 28 (7.0) 176 (21.8) 0.24 (0.15 - 0.37) <0.001 
   (at least monthly use vs no use)     
Infrequent use 61 (15.3)  159 (19.7) 0.58 (0.41 - 0.82) <0.001 
(less than monthly use vs. no use)     
No use reported* 311 (77.8) 473 (58.7)   
Age Median (IQR) 22.4 (21-24) 21.5 (20-23)  <0.001 
Male gender 254 (63.5) 575 (71.2) 0.70 (0.55 - 0.91) 0.008 
White ethnicity 299 (74.8) 516 (63.9) 1.68 (1.28 - 2.19) <0.001 
Education (≥ secondary) 138 (34.5) 296 (36.6) 0.90 (0.70 - 1.16) 0.445 
Regular employment† 176 (44.0) 482 (59.7) 0.53 (0.42 - 0.68) <0.001 
Homelessness† 311 (77.8) 588 (72.8) 1.32 (0.99 - 1.75) 0.057 
DTES residence† 158 (39.5) 192 (23.8) 2.09 (1.62 - 2.71) <0.001 
Drug treatment† 173 (43.3) 197 (24.4) 2.35 (1.82 - 3.04) <0.001 
Non-injection prescription opioids† 76 (19.0) 93 (11.5) 1.78 (1.28 - 2.47) 0.001 
Non-injection crack cocaine† 283 (70.8) 589 (72.9) 0.87 (0.67 - 1.14) 0.337 
Non-injection methamphetamine† 215 (53.8) 323 (40.0) 1.72 (1.35 - 2.19) <0.001 
Non-injection heroin† 143 (35.8) 145 (17.9) 2.53 (1.92 - 3.32) <0.001 
Daily cannabis† 137 (34.3) 390 (48.3) 0.55 (0.43 - 0.71) <0.001 
Heavy alcohol † 83 (20.8) 345 (42.7) 0.35 (0.26 - 0.46) <0.001 
Mental illness diagnosis 633 (52.4) 575 (47.6) 1.47 (1.14 - 1.88) 0.002 
Emotional abuse 563 (46.6) 549 (45.4) 1.20 (0.93 - 1.56) 0.158 
Emotional neglect 532 (44.0) 574 (47.5) 1.45 (1.11 - 1.88) 0.004 
Physical Abuse 321 (26.6) 791 (65.5) 1.14 (0.85 - 1.51) 0.357 
Physical neglect 333 (27.6) 778 (64.4) 1.06 (0.80 - 1.40) 0.725 
Sexual abuse 187 (15.5) 912 (75.5) 1.32 (0.93 - 1.85) 0.102 
† Denotes activities in the previous six months 
*six participants reported MDMA use at baseline did not report frequency of use, and were excluded 
IQR= Interquartile range 
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Table 2. Bivariable and multivariable generalized estimating equations (GEE) analyses of factors 
associated with use of injection drugs among 1208 at-risk youth in Vancouver, Canada. 
 Unadjusted  Adjusted 
Characteristic 
Odds Ratio 
(95% CI) 
p - value 
 Odds Ratio 
(95% CI) 
p - 
value 
MDMA†      
Regular Use  
(at least monthly use vs no use) 
0.60 (0.50-0.72) <0.001 
 
0.57 (0.46-0.69) <0.001 
Infrequent Use  
(less than monthly use vs. no use) 
0.99 (0.86-1.15) 0.912 
 
0.95 (0.81-1.11) 0.514 
Age at baseline      
(per year older) 1.1 (1.05-1.14) <0.001    
Gender      
(men vs. women) 0.78 (0.62-0.97) 0.027    
Ethnicity      
(White vs. non-White) 1.43 (1.14-1.80) 0.002    
Education      
(≥ secondary vs. < secondary) 0.89 (0.71-1.12) 0.315    
Employment†      
(yes vs. no) 0.77 (0.69-0.86) <0.001    
Homelessness†      
(yes vs. no) 1.17 (1.04-1.31) 0.008  1.21 (1.08-1.36) 0.002 
DTES residence†      
(yes vs no)  1.39 (1.24-1.57) <0.001    
Drug treatment†      
(yes vs no) 1.21 (1.08-1.37) 0.002    
Non-injection prescription opioids†      
(yes vs. no) 1.29 (1.08-1.55) 0.006  1.35 (1.11-1.65) 0.002 
Non-injection crack cocaine†      
(yes vs. no) 1.03 (0.92-1.17) 0.579    
Non-injection methamphetamine†      
(yes vs. no) 1.38 (1.22-1.56) <0.001    
Non-injection heroin† 
 
     
(yes vs. no) 1.58 (1.34-1.87) <0.001    
Daily Cannabis†      
(yes vs. no) 0.81 (0.72-0.91) 0.001    
Heavy alcohol †      
(yes vs. no) 0.69 (0.61-0.78) <0.001  0.71 (0.63-0.81) <0.001 
Mental illness diagnosis      
(yes vs. no) 1.42 (1.18 -1.72) <0.001    
Emotional abuse      
(moderate/severe vs, none/low) 1.27 (1.02 -1.58) 0.035    
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Emotional neglect      
(moderate/severe vs, none/low) 1.50 (1.20 -1.88) <0.001    
Physical Abuse      
(moderate/severe vs, none/low) 1.28 (1.01 -1.64) 0.043  1.25 (0.98-1.59) 0.075 
Physical neglect      
(moderate/severe vs, none/low) 1.18 (0.92 -1.50) 0.187    
Sexual abuse      
(moderate/severe vs, none/low) 1.26 (0.94 -1.67) 0.116    
† Denotes activities in the previous six months.  
